Plain-English translation of NCT06179524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called CAR-T-19 Injection for young people under 25 whose acute lymphoblastic leukemia (a type of blood cancer) has come back or stopped responding to standard chemotherapy. The treatment uses your own immune cells, which are collected, specially trained in a lab to fight the cancer, and then given back to you. This medication represents a different approach to treating this cancer, one that teaches your body's immune system to recognize and destroy the leukemia cells.
Many young patients with relapsed or treatment-resistant acute lymphoblastic leukemia have very limited options, and standard chemotherapy is no longer working for them. This trial exists to see if this new immune cell-based approach can help these patients achieve remission and improve their chances of survival.
You likely qualify if…
You likely don't qualify if…
If you're accepted into the study, you'll first have a procedure called leukapheresis to collect your own immune cells from your blood. Your cells will then be sent to a lab where they'll be modified to recognize and fight your cancer. While your cells are being prepared, you'll receive chemotherapy to prepare your body for the new cells. After about 3 days of chemotherapy, you'll receive an infusion of your treated immune cells back into your body. You'll then need close medical monitoring to watch for how your body responds, with regular blood tests and visits to track your progress.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China